Alpek's $276 Million Quarter That Only Minted $5 Million of Cash
Leverage is below target and guidance is up, but working capital and moderating spreads are the real story.
ALPEKA.MX · Earnings Call · 2026-10-22
Alpek's third quarter looked like a clean cyclical victory lap. Comparable EBITDA of $276 million doubled year over year; reported EBITDA rose 161% to $303 million; management lifted full-year 2026 comparable EBITDA guidance to $990 million; and leverage fell to 1.8x, below the company's 2.0x-2.5x target range. The CEO called it another exceptional quarter and pointed to capacity cuts—installed capacity down 15% and headcount down 29% since 2023—as proof the operating model is working. Then the cash-flow line interrupts the celebration.
We generated $5 million in operating free cash flow. As higher reported EBITDA was offset by a larger than anticipated investment of $226 million in net working capital.
That is the central tension. Alpek is earning a trade-disruption windfall, but the windfall is being stored in working capital rather than converted into cash. For a company whose equity story has been deleveraging and financial flexibility, that distinction matters more than the EBITDA beat.
The windfall is freight and spreads, not volume alone
Q3 Chinese integrated PET reference margins averaged $213 per ton, down 31% sequentially but still 59% above 2025. Ocean freight to South America averaged $321 per ton, up 43% quarter over quarter and 74% year over year. Those two variables—freight rate and PET reference margins—are doing most of the work. The company's guidance assumes Chinese PET margins of $225 per ton and freight of $100 per ton for the rest of 2026. The PET assumption is above the Q3 average; the freight assumption is far below it. That is a deliberately conservative-looking mix, but it also tells you where the risk sits: if freight normalizes toward $100, much of the import-parity support fades, and if PET margins moderate as management expects, the EBITDA base compresses from both sides.
Management is explicit that spreads should come down. “we expect the spreads to ... moderate ... they might remain above 25 levels” — Jorge Pedro Young Cerecedo, CEO · 2026-10-22 The caveat is the new structural argument: Asian producers had access to discounted sanctioned oil, and that access is now impaired. Access to sanction discounted oil is a fresh keyword in the company's trajectory, and it is the bullish counterpoint to the spreads-must-normalize view. If Asian supply discipline stays impaired, Chinese PET margins may hold above 2025 levels longer than the guidance assumes. If access returns, the floor cracks.
Volume was solid at 1.17 million tons, flat sequentially and up 4% year over year, but the CEO was careful about the source. He said the gains were mostly import share gains, with some help from a good beverage season around the World Cup football matches. That is not the same as a demand recovery. The local supplier premium is real—management says customers pay a reliability premium versus import parity—but it is a commercial advantage that shrinks when trade lanes normalize, not a perpetual margin.
Working capital is the tell
The $226 million working-capital investment came mainly from higher absolute prices, especially paraxylene at multiyear highs. Management's defense is that days of working capital are normal; the problem is unit prices, not collections or inventory discipline. “the only issue is unit prices. And unit prices have increased significantly because of the oil increases” — Jorge Pedro Young Cerecedo, CEO · 2026-10-22 That is a clean explanation, and it is probably true. But it also means the release of cash is a price call, not an operating call. If raw materials moderate, working capital unwinds proportionally; if they stay high, the cash stays trapped.
The unchanged free-cash-flow guidance is the proof. Alpek raised comparable EBITDA guidance to $990 million but kept operating free cash flow at $300 million-$350 million and net debt reduction at $200 million-$250 million. CFO Rodrigo Prieto said the reason was working capital: the company expects some recovery, but not all of it. The EBITDA raise is real, but the cash conversion is not being upgraded with it. That is why the quarter's headline beat and the $5 million of operating free cash flow can both be true.
Asset monetization is still part of the bridge. Alpek has closed about $14 million year to date against a $30 million-$50 million target for 2026. Lower leverage has not slowed the program, management insists, because the assets are non-core land parcels. The Monterey site is being prepared for a sale in a couple of years at a higher value. But the numbers are small relative to $1.72 billion of net debt. Asset sales help at the margin; they do not solve the cash-conversion issue.
Below target, but not yet declaring victory
The leverage move is the genuinely new fact. In February, the CFO said “we don't expect to get to the level of 2.5x this year. It's something that can happen in 2027.” — José Pons, Chief Financial Officer · 2026-02-11 By July, the company was still prioritizing deleveraging and saying it would end the year without further dividends. Three months later, leverage is 1.8x and the CEO's prepared remarks even put it at 2.0x—a small inconsistency that captures the mood. The company is below target, but management is not acting like the cycle is safely past. financial flexibility and debt reduction remain the top two priorities. The CFO was direct: “before we talk about any dividends, we are very focused on reducing debt” — Rodrigo Prieto Treviño, CFO · 2026-10-22 Dividends get evaluated in the first quarter of 2027, not now.
The capital-allocation ranking is debt reduction first, high-return organic capex second, and opportunistic M&A plus dividends third. That is a conservative sequence, and it explains why a below-target leverage ratio has not produced a capital-return announcement. Management is implicitly assuming mid-cycle EBITDA is lower than the current trailing number. The CEO said a mid-cycle number between 2025, 2026 and 2027 should put leverage in range or below it, but he also wants absolute debt lower before pursuing the project pipeline. In other words: the balance sheet is fixed faster than expected, but the company does not trust the earnings base enough to declare the deleveraging finished.
This is where the prior-call contrast is sharpest. The Q2 keyword list was dominated by domestic supplier, spot sales, leverage ratio and asset sales. The current list is topped by freight rate, financial flexibility, cost pressures, unit prices and debt reduction. The conversation has moved from winning volume because imports are disrupted to the windfall being price-dependent, with the cash not fully in hand yet. That is a more cautious story than the guidance raise implies.
The bottom line
Alpek's quarter is a high-quality operating result wrapped in a low-quality cash result. The company is benefiting from a genuine trade disruption—elevated freight, impaired Asian feedstock access, and a local-supplier premium—and it has used the EBITDA to cut leverage below target far faster than anyone expected. But the same disruption has inflated the working capital base, and management's own guidance assumes freight and spreads normalize from here. If they do, the cash comes back but the EBITDA tailwind fades. If they do not, the EBITDA stays high but the cash stays stuck. Either way, the next few quarters are less about whether Alpek can earn a cyclical margin and more about whether it can convert that margin into the deleveraging and capital returns that the equity story now promises.